Back to discover
Disease

Urogenital Neoplasms

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHUrogenital Neoplasms
3
Publications
18
Clinical trials
3
Related conditions
1
Related treatments
5
Associated genes
1
Related proteins
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones5View
Results posted 2
Results expected 3
Activity timeline5

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

15 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
3
Late-stage
6
Completed
Late-stage studies

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

Phase 4 · Recruiting · VA Greater Los Angeles Healthcare System

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 · Active, not recruiting · Eli Lilly and Company

A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)

Phase 3 · Withdrawn · Medical Enterprises Europe B.V.
Recruiting

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

Phase 4 · Recruiting · VA Greater Los Angeles Healthcare System

A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 · Recruiting · Sheba Medical Center

A Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAM

Phase 2 · Recruiting · The Netherlands Cancer Institute

A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney Cancer

Phase 2 · Recruiting · RenJi Hospital
Recently completed

High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy or Radical Prostatectomy

Phase 2 · Completed · Alessandro D'Agnolo

Phase 1/2 Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in Subjects With Urothelial Carcinoma

Phase 1/2 · Completed · NanOlogy, LLC

An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy

Phase 2 · Completed · Novartis Pharmaceuticals

A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Phase 2 · Completed · Eli Lilly and Company

A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma

Phase 2 · Completed · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase II Trial of Motexafin Gadolinium for Treatment of Metastatic Renal Cell Carcinoma

Phase 2 · Completed · Pharmacyclics LLC.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20152024
Most influential

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Advances in anatomic pathology · 2017 · 607 cites

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

PloS one · 2015 · 350 cites

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 18 cites
Recent publications

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 18 cites

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Advances in anatomic pathology · 2017 · 607 cites

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

PloS one · 2015 · 350 cites
Major themes6
  • Anilides1
  • Antineoplastic Combined Chemotherapy Protocols1
  • Ipilimumab1
  • Nivolumab1
  • Pyridines1
  • Urogenital Neoplasms1
Leading journals3
  • Advances in anatomic pathology1
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
  • PloS one1
Leading researchers8
  • Adams S1
  • Agarwal PK1
  • Akbulut D1
  • Allison KH1
  • Allory Y1
  • André F1
  • Apolo AB1
  • Badve S1
Affiliations (unnormalised)6
  • Center for Cancer Research1
  • Center for Onco-Immunology1
  • City of Hope Comprehensive Cancer Center1
  • Clinical Center1
  • College of Medicine1
  • Herbert Irving Comprehensive Cancer Center1

Associated genes

5 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

NECTIN40.33SFXN50.01KRCC10.01OR2L50.01TBC1D8B0.01

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Nectin-4via NECTIN40.33

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Carcinoma, Non-Small-Cell Lung2Lung Neoplasms2Melanoma2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.

Identifiers
MeSHUrogenital Neoplasms
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.